ClinicalTrials.gg
CompletedNCT03310931Updated Oct 16, 2017

Predictive Significance of TEG on END in Patients With Acute Ischemic Stroke

An observational study in Acute Ischemic Stroke, sponsored by Dongguan People's Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-16.

Sponsored by Dongguan People's Hospital · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Enrollment
134th of 187
200 · median 650
Started
2016
with 20 others
Observational
187 of 750
107 open now
Registered
94th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 134th largest by enrollment of the 187 observational ones that give a count, is one of 21 that started in 2016, is one of 187 observational ones, and was the 94th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether Thromboelastography (TEG) parameters on admission might be predictive for early neurological deterioration in acute ischemic stroke patients, specifically for the DWI lesion evolution within the first week after stroke onset.

Read the detailed description

Early neurological deterioration (END ) is a major concern in stroke care, consistently associated with adverse clinical outcomes.END is a heterogeneous complex of pathophysiological and clinical entities. Despite some straight forward causes, DWI lesion growth is reportedly a primary underlying mechanism. Early recognition of END risk would allow for timely identification and proper intervention, improving stroke health care.

Thromboelastography (TEG) measures the coagulation process from initial clotting cascade to clot strength, providing an integrated picture of two separate but simultaneously occuring components of coagulation, thrombosis and lysis. It has been reported to be associated with short and long-term outcome in patients with trauma, coronary artery diseases , pulmonary embolism and, most recently, stroke prevention.The purposes of this study is to evaluate how effective TEG is on predicting END, by producing a range of TEG values correlated with clinical and radiological assessment.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes consecutively admitted patients with acute ischemic stroke in Dongguan people's Hospital. Patients would take TEG study within 6 hours after admission, as well as other routine lab tests. Serial MRI studies would be taken on admission and followed up on 7th day afterward, except when patients experience END, in which case followup MRI should be preformed immediately.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute ischemic stroke within 24 hours after symptom onset
  • first ever stroke
  • give

Exclusion criteria

Exclusion Criteria:

  • receiving thrombolysis
  • cardiogenic embolism
  • contradiction to serial MRI studies
  • taking hemostatic agents (warfarin, oral anticoagulants and etc. )
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • End and non-END groups

    END was denied as NIHSS score increase of 2 or more than 2 within 7 days after admission

06

What researchers measure

Primary outcomes

  1. END

    increase of NIHSS \>=2

    Time frame: fist week after admission

Secondary outcomes

  1. DWI lesion growth

    Large volume or new lesions on followup DWI than the baseline DWI

    Time frame: 7 days

07

Study locations

1 site
  • Dongguan peoples' hospital
    Dongguan, Guangdong 523029, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Sep 2017, 15 months.

Of 397 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's 15 months is below that.

Counting every sponsor, half of 439 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2017
First posted
Oct 16, 2017
StartActual
Jun 1, 2016
Primary completionActual
Sep 30, 2017
CompletionActual
Sep 30, 2017
Last update
Oct 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03310931
Lead sponsor
Dongguan People's Hospital
Responsible party
Zhu Shi (MD, Deputy Director of Neurology Department, Dongguan People's Hospital) — Principal investigator
First posted
Oct 16, 2017
Start date
Jun 1, 2016
Primary completion
Sep 30, 2017
Completion
Sep 30, 2017
Last update
Oct 16, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion